Plain-English translation of NCT06007092 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a therapeutic vaccine called CD40HVac that is designed to help your immune system fight HPV-positive throat cancer. The vaccine is being given to people who have already completed surgery and/or radiation therapy and have no signs of remaining cancer. The goal is to see if the vaccine can help prevent the cancer from coming back and whether it's safe to use.
Even after surgery and radiation, some people with HPV-positive throat cancer experience cancer recurrence. This medication is designed to teach your immune system to recognize and attack any remaining cancer cells, offering a new way to reduce the risk of the cancer returning.
You likely qualify if…
You likely don't qualify if…
You will receive three injections of either the vaccine or placebo (a dummy injection with no medicine) over approximately 6 months — at the start, at 4 weeks, and at 24 weeks. Most participants (10 out of 12 in each dose group) will receive the real vaccine, while a few will receive placebo. You'll have regular blood tests and check-ups to monitor your safety and how your immune system responds. The entire study lasts several months, and you'll be carefully watched for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France